Isatuximab, Carfilzomib, Pomalidomide, and Dexamethasone for the Treatment of Relapsed or Refractory Multiple Myeloma
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies the effect of isatuximab, carfilzomib, pomalidomide, and
dexamethasone in treating patients with multiple myeloma that has come back (relapsed) or
does not respond to treatment (refractory). Isatuximab is a monoclonal antibody that may
interfere with the ability of cancer cells to grow and spread. Carfilzomib may stop the
growth of cancer cells by blocking some of the proteins needed for cell growth. Chemotherapy
drugs, such as pomalidomide, work in different ways to stop the growth of cancer cells,
either by killing the cells, by stopping them from dividing, or by stopping them from
spreading. Anti-inflammatory drugs, such as dexamethasone lower the body's immune response
and are used with other drugs in the treatment of some types of cancer. Giving isatuximab,
carfilzomib, pomalidomide, and dexamethasone may kill more cancer cells.